Glenza 160 mg Tablets

Enzalutamide belongs to a class of medications known as androgen receptor inhibitors, which work by blocking multiple steps in the androgen receptor signaling pathway that prostate cancer cells rely on to grow. Unlike some earlier anti-androgen therapies, Enzalutamide binds more strongly to androgen receptors and also helps prevent the receptor from moving into the cell nucleus, providing a more thorough block of hormone-driven cancer growth. It is commonly used in the treatment of advanced or metastatic prostate cancer, including cases that continue to progress despite standard hormone therapy, offering an important option for patients needing further disease control. As an oral targeted therapy, Enzalutamide offers a convenient treatment option, allowing much of the treatment to take place at home between clinical check-ins. It is typically taken once daily, following a schedule established by an oncologist or urologist based on the patient's specific condition and treatment history. Regular monitoring, including prostate-specific antigen (PSA) level checks and imaging studies, is an important part of treatment to help track the body's response and guide any necessary adjustments. Many patients experience meaningful disease control and improved quality of life with consistent use of Enzalutamide as part of their treatment plan. As with all targeted hormone therapies for prostate cancer, Enzalutamide should be used strictly under the guidance of an experienced oncology or urology healthcare provider.